Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies announced a clinical strategy to treat patients with moderate to severe COVID-19 who require hospitalization. ATR-002, an oral small molecule, has been proven in preclinical trials to block viral propagation of SARS-CoV-2 and to have an immunomodulatory effect leading to a decreased cytokine and chemokine release. This dual benefit makes the MEK-inhibitor ATR-002 particularly relevant for the treatment of COVID-19.
source https://www.pharmatutor.org/pharma-news/2020/atriva-therapeutics-to-develop-atr-002-for-treatment-of-patients-with-covid-19-in-phase-ii-study
No comments:
Post a Comment